Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-27T04:31:53.272Z Has data issue: false hasContentIssue false
  • English
  • Français

Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication

Published online by Cambridge University Press:  16 May 2017

Manish Aggarwal  and
Ronald Mark Grady
Manish Aggarwal*
Affiliation:
Division of Pediatric Cardiology, Washington University in St. Louis, St. Louis, Missouri, United States of America
Ronald Mark Grady
Affiliation:
Division of Pediatric Cardiology, Washington University in St. Louis, St. Louis, Missouri, United States of America
*
Correspondence to: M. Aggarwal, MD, Division of Pediatric Cardiology, Washington University in St. Louis , One Children’s Place, St. Louis, MO 63108, United States of America. Tel: 314-454-6095; Fax: 314-454-2561; E-mail: aggarwal_m@kids.wustl.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Laboratory investigations have shown the role of inflammation in the pathogenesis of pulmonary hypertension and improvement after anti-inflammatory drugs. Despite these observations, reports on the use of steroids to treat pulmonary hypertension in humans are absent from the literature. In this article, we report the use of glucocorticoids in the treatment of two children with pulmonary hypertension, demonstrating its potential utility.

Keywords

Pulmonary hypertensioninflammationglucocorticoids
Type
Brief Report
Information
Cardiology in the Young , Volume 27 , Issue 7 , September 2017 , pp. 1410 - 1412
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Simonneau, G, Gatzoulis, MA, Adatia, I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl): D34–D41.Google Scholar
2. Price, LC, Wort, SJ, Perros, F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141: 210–221.Google Scholar
3. Wang, W, Wang, YL, Chen, XY, et al. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep 2011; 38: 3277–3284.Google Scholar
4. Price, LC, Montani, D, Tcherakian, C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011; 37: 813–822.Google Scholar
5. Ogawa, A, Nakamura, K, Matsubara, H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005; 112: 1806–1812.Google Scholar
6. Ogawa, A, Nakamura, K, Mizoguchi, H, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183: 139–140.Google Scholar
7. Hassoun, PM, Rather, L, Heidland, A, et al. Inflammation in pulmonary arterial hypertension: is it time to quell the fire? Eur Respir J 2014; 43: 685–688.Google Scholar